Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: A self-controlled before-after trial

CONCLUSION: Telitacicept combined with the standard treatment may significantly increase the SRI-4 response rate and reduce the glucocorticoid dosage in refractory cSLE, and also shown efficacy on lupus nephritis. The related adverse drug events were controllable.PMID:35499216 | DOI:10.1177/09612033221097812

Source: Lupus - May 2, 2022 Category: Rheumatology Authors: Li Sun Qian Shen Yinv Gong Yifan Li Qianying Lv Haimei Liu Fei Zhao Haiguo Yu Lingzhi Qiu Xiaozhong Li Xiaoliang He Yuqing Chen Zhiquan Xu Hong Xu Source Type: research